U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07439042) titled 'Buspirone for Anxiety in Autistic Youth' on Feb. 13.
Brief Summary: The purpose of the study is to do a preliminary trial to determine if buspirone is effective, safe, and tolerable in autistic youth with anxiety.
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
Anxiety
Autism Spectrum Disorder
Intervention:
DRUG: buspirone
Buspirone, an anxiety medication that is FDA approved for generalized anxiety disorder in adults, will be the active comparator for this trial.
DRUG: Placebo
Matching placebo capsules/liquid formulation will be prepared.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Massachusetts Ge...